A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Mar 2018

At a glance

  • Drugs Rivaroxaban (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ATLAS-2-TIMI-51; ATLAS-ACS-2-TIMI-51
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 12 Mar 2018 Results of pooled analysis of ATLAS-ACS-TIMI-46, ATLAS-ACS-2-TIMI-51, GEMINI-ACS-1, and COMPASS trial comparing efficacy and safety of Rivaroxaban based dual pathway antithrombotic therapy Vs dual antiplatelet therapy presented at the 67th Annual Scientific Session of the American College of Cardiology
    • 09 Aug 2017 This trail is dicontinued in Belgium as Eudra.
    • 16 Nov 2016 Results presented at the 89th Annual Scientific Sessions of the American Heart Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top